Fractyl Health Inc. has announced positive 6-month results from its open-label REVEAL-1 Cohort study. The study involved individuals with obesity who had lost at least 15% of their total body weight on a GLP-1 medication and had either discontinued or needed to discontinue GLP-1 therapy. Participants who underwent a single Revita procedure after stopping GLP-1 therapy maintained stable body weight and glycemic control over six months. The company also reported a 1.5% mean weight change among the 17 participants, compared to approximately 10% weight regain typically observed in similar patients who discontinue GLP-1 therapy without further intervention. Upcoming randomized 6-month data from the REMAIN-1 Midpoint Cohort are expected in January 2026, with additional clinical readouts and a potential Premarket Approval (PMA) filing for Revita anticipated in the second half of 2026.